Recommendations for the Use of Antiretroviral Drugs in Pregnant Women with HIV Infection and Interventions to Reduce Perinatal HIV Transmission in the United States

The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.

  •   Table of Contents

Download Guidelines

Protease Inhibitors

Tipranavir (Aptivus, TPV)

Last Updated: December 7, 2018; Last Reviewed: December 7, 2018

Excerpt from Table 10a
Generic Name
(Abbreviation)
Trade Name
Formulation Dosing Recommendations Use in Pregnancy
Tipranavir
(TPV)
Aptivus

Note:
Must be combined with RTV for PK boosting
TPV (Aptivus) 
Capsules
  • 250 mg
Oral Solution:
  • 100 mg/mL
Standard Adult Dose:
  • TPV/r 500 mg/200 mg twice daily
With RTV Tablets:
  • Take with food.
With RTV Capsules or Solution:
  • Take without regard to food; however, administering with food may help make the dose more tolerable.

Dosing in Pregnancy:
  • Insufficient data to make dosing recommendation

PK in Pregnancy:
  • Limited PK data in human pregnancy
TPV should not be used during pregnancy.

Moderate placental transfer to fetus reported in 1 patient.b

Insufficient data to assess for teratogenicity in humans. No evidence of teratogenicity in rats or rabbits.

Must be given as low-dose RTV-boosted regimen.

a Individual ARV drug dosages may need to be adjusted in patients with renal or hepatic insufficiency (for details, see the Adult and Adolescent Guidelines Appendix B, Table 8).
b Placental transfer categories are determined by mean or median cord blood/maternal delivery plasma drug ratio:
          High: >0.6
          Moderate: 0.3–0.6
          Low: <0.3

Key to Acronyms:]PK = pharmacokinetic; RTV = ritonavir; TPV = tipranavir; TPV/r = tipranavir/ritonavir

Download Guidelines